Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal disorders and diseases. The Company’s lead drug candidate, Atiprimod, is being developed as a treatment for carcinoid cancer. Callisto’s second drug candidate, L-Annamycin, is being developed to treat relapsed acute leukemia. A third drug candidate, SP-304 (guanilib), is being developed as a treatment for gastrointestinal disorders.
(Source: 10-K)
